<?xml version="1.0" encoding="UTF-8"?>
<p id="p0160">Further information and requests for resources and reagents should be directed to the Lead Contact, Surender Khurana (
 <ext-link ext-link-type="uri" xlink:href="mailto:Surender.Khurana@fda.hhs.gov" id="intref0015" xmlns:xlink="http://www.w3.org/1999/xlink">Surender.Khurana@fda.hhs.gov</ext-link>). There are restrictions to the availability of the GFPDL technology and Ebola peptides described in this study due to US patent application.
</p>
